Novavax, Inc. (NVAX)
Pre-Market: 05:29AM EDT
| Previous Close | 166.25 |
| Open | 167.42 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 3200 |
| Day's Range | 160.25 - 173.37 |
| 52 Week Range | 76.59 - 331.68 |
| Volume | 2,962,992 |
| Avg. Volume | 5,024,323 |
| Market Cap | 11.958B |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.84 |
| Earnings Date | Nov. 08, 2021 - Nov. 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 264.20 |
- Editor's PickYahoo Finance Video
How innovations in Covid-19 testing will play a part in this winter season
Thierry Bernard, QIAGEN CEO, joins Yahoo Finance to discuss the future of Covid-19 testing, interest and supply of at-home covid testing, and the diagnostic industry amid the pandemic.
- Motley Fool
5 of the Fastest-Growing Stocks On the Planet
For instance, AMC Entertainment (NYSE: AMC) reported 2,252% revenue growth in its most recent quarter. Last year at this time, the COVID-19 lockdown was crushing a lot of stocks, with revenues dropping to near-zero for many companies. While some of these stocks are "turn around" stories, all of the stocks in this article have strong financials and are way safer than AMC.
- Motley Fool
Why Shares of Moderna, Novavax, and Ocugen Are Falling Today
Shares of Moderna (NASDAQ: MRNA) are off by 3.4%; Novavax (NASDAQ: NVAX) is down 5.1%; and Ocugen's (NASDAQ: OCGN) stock is in the red by a jaw-dropping 13.3%, all as of 3:34 p.m. EDT Friday. The U.S. Food and Drug Administration (FDA) might delay the decision on Moderna's jab for adolescents due to safety issues, according to a report from the Wall Street Journal.
